ESPERITE (ESP) financial results for 2014 published, metamorphosis completed, first positive forecast growth at 36mio …

Stem cell historical CryoSave's core business now profitable and improving

Consolidated operations, headcount rationalization, integrated sales and marketing strategies, laboratories integration and processes automatization completed to yield enhanced performance and results

Zutphen,The Netherlands-17March 2015

Frederic Amar, appointed ESPERITE CEO on March 2014, is implementing from the onset an aggressive reorganization and development of the company. Frederic Amar's far-reaching new business model has materialized in three separate synergetic business units attacking new markets with a diversified offer, transforming a mono-product business model into a biotech multiservice company. ESPERITE's consolidated operations feature now reduced complexity, sustainable lower overhead, centralized administrative services, integrated sales and marketing strategies coupled with the technology to handle large volumes efficiently. The preliminary (unaudited) financial results for year ended 31 December 2014 published today reflect these improvements.

Frederic Amar, CEO of ESPERITE: "ESPERITE, both an aspiration and inspiration, reborn on July 2014 to signal a whole new way of doing business and create growth. It was a year of strong impulse and fierce implementation of new ideas. Execution exceeded expectations and results will too. I am proud of our achievements this year transforming a fragile company into an ambitious start-up. Our strategic investments and mastery of technology brings ESPERITE to pole position".

Financial highlights

Revenue 27.6 million (2013: 29.8 million) Gross profit as percentage of revenue 62.2% (2013: 64.5%) Underlying* operating expenses before depreciation, amortization and impairments: 17.7 million (2013: 18.7 million) Underlying EBITDA**: -0.56 million (2013: 0.5 million)

Underlying EBITA***: -2.1 million (2013: -1.0 million) Underlying operating result: -3.4 million (2013: -2.3 million)

See the original post here:
ESPERITE (ESP) financial results for 2014 published, metamorphosis completed, first positive forecast growth at 36mio ...

Wu Medical Center – A Leading Medical Center for Stem Cell …

WuMedical Center (WMC) was named after Dr. Like Wu, the co-Founder, Chief Neurologist and Managing Director of the center. Using the unique stem cell technologies innovated by Dr. Wu, since 2005, he and his medical team have successfully treated over 2,000 patients from all over the world suffering from various neurological diseases, disorders, and injuries including Parkinson's disease, post-stroke, Batten's disease, ALS, MS, MSA, PSP, cerebral palsy, traumatic brain and spinal cord injuries, etc. This has laid a solid foundation for the application of stem cell technologies to treat these previously untreatable neurological diseases.

To make a world of difference in the lives of patients and their families by integrating new medical technologies, care, education and research to provide the highest quality care and service to our diverse community.

WSCMC will be one of the best stem cells medical centers in the world, known for advancing research and providing definitive diagnosis and treatment for our diverse community of patients with complex neurological diseases.

See the original post here:
Wu Medical Center - A Leading Medical Center for Stem Cell ...

Eight-year-old girl meets her stem cell donor

Terrence Antonio James

FRIENDS FOR LIFE: Sabrina Chahir, who received a marrow transplant in 2011, meets her donor, Maximilian Eule, left, a German who came in from Austria to meet her, at a restaurant in Illinois earlier this month.

Sabrina Chahir was waiting to meet the man who helped send her cancer into remission.

The 8-year-old girl from the United States, who likes art and takes piano lessons, knew he had flown across an ocean to see her, nearly four years after he donated his stem cells to help rid her blood of cancer that could have taken her life.

Recently Sabrina and Maximilian Eule, 30, had their first face-to-face meeting at a celebration in suburban Schaumburg, Illinois with Sabrina's friends and family.

The two had emailed and video-chatted. But Sabrina's mother, Natalia Wehr, said it was important to her to meet Eule in person.

"It's your daughter, and this person we don't know did something so wonderful," Wehr said. "You need to know who that is."

SABRINA'S STORY - DIAGNOSED AT TWO

Sabrina was diagnosed with acute lymphoblastic leukemia, one of the most common types of cancer in children, when she was 2. The cancer cells were in more than 80 percent of her blood.

The girl's cancer had gone into remission before, but she soon relapsed. After rounds of treatment and infections that caused Sabrina to go blind temporarily, doctors at Lurie Children's Hospital of Chicago told Sabrina's family she would need a stem cell transplant.

Continue reading here:
Eight-year-old girl meets her stem cell donor

Stem Cell Research & Therapy | Full text | Amnion-derived …

Fauza D: Amniotic fluid and placental stem cells.

Best Pract Res Clin Obstet Gynaecol 2004, 18:877-891. PubMedAbstract | PublisherFullText

Parolini O, Alviano F, Bagnara GP, Bilic G, Bhring HJ, Evangelista M, Hennerbichler S, Liu B, Magatti M, Mao N, Miki T, Marongiu F, Nakajima H, Nikaido T, Portmann-Lanz CB, Sankar V, Soncini M, Stadler G, Surbek D, Takahashi TA, Redl H, Sakuragawa N, Wolbank S, Zeisberger S, Zisch A, Strom SC: Concise review: isolation and characterization of cells from human term placenta: outcome of the first international workshop on placenta derived stem cells.

Stem Cells 2008, 26:300-311. PubMedAbstract | PublisherFullText

Pozzobon M, Ghionzoli M, De Coppi P: ES, iPS, MSC, and AFS cells. Stem cells exploitation for Pediatric Surgery: current research and perspective.

Pediatr Surg Int 2010, 26:3-10. PubMedAbstract | PublisherFullText

Miki T, Marongiu F, Dorko K, Ellis EC, Strom SC: Isolation of amniotic epithelial stem cells.

Curr Protoc Stem Cell Biol 2010, Chapter 1:Unit 1E 3. PubMedAbstract | PublisherFullText

Miki T, Strom SC: Amnion-derived pluripotent/multipotent stem cells.

Stem Cell Rev 2006, 2:133-142. PubMedAbstract | PublisherFullText

See the rest here:
Stem Cell Research & Therapy | Full text | Amnion-derived ...

OSKM stoichiometry determines iPS cell reprogramming

13 hours ago (top) Adding 9 amino acids before Klf4 to switch the isoform from Klf4S to Klf4L subtly lengthens the transgene. (bottom left) This lengthening causes a significant increase in the Klf4 protein expression. (bottom right) It also increases the proportion of reprogrammed cells (green) to partially reprogrammed cells (red). Credit: Dr. Knut Woltjen's Laboratory

Researchers at Kyoto University's Center for iPS Cell Research and Application discover a simple way to increase the production of induced pluripotent stem cells. A major hurdle in reprogramming science is generating a sufficient number of iPS cells to conduct basic research experiments. Yet, a report published in Stem Cell Reports shows that simply adding 9 amino acids to the induction transgene Klf4 dramatically elevates the production of fully reprogrammed mouse iPS cells.

Anyone in the field of cell reprogramming recognizes Oct3/4, Sox2, Klf4, and c-Myc, or "OSKM", as the Yamanaka factors that led to the first iPS cells. Originally, these four genes were delivered as individual (monocistronic) viral vectors. In order to simplify protocols, researchers began to deliver them using single polycistronic vectors, where the OSKM genes are linked as mRNA but still produce four separate proteins to induce reprogramming. However, not all vectors are built the same, and it turns out their subtle variations may influence both reprogramming efficiencies and outcomes. Specifically, the length of Klf4 appears to be a significant factor in determining whether a somatic cell is reprogrammed to the pluripotent state. Klf4 was first reported in 1996 by two independent studies. However, despite investigating the same gene, those two reports predicted different locations of the start codon in the mRNA sequences, which when translated result in proteins that differ by nine amino acids in length. Which isoform is used for reprogramming depends on the lab. "Some labs use short Klf4, some labs use long. Some labs have even switched between the two lengths," says Knut Woltjen, Ph.D., Associate Professor at CiRA.

Curious if these amino acids could explain the diverse reprogramming efficiencies that have been reported by different labs, Woltjen and his team employed piggyBac transposons to deliver various polycistronic reprogramming factors, controlling for the Klf4 length. They found that transfection with polycistronic vectors carrying the shorter Klf4 (Klf4S) resulted in more cells that initiated reprogramming, but failed to complete it, leaving them as partially reprogrammed. In contrast, the majority of cells transfected with vectors carrying the longer Klf4 (Klf4L) became true iPS cells. Deeper investigation found that polycistronic vectors with the Klf4L isoform showed much higher Klf4 protein expression, suggesting that the stoichiometry of the reprogramming factors could be the critical factor underlying reprogramming efficiency. According to Woltjen, "The stoichiometry is so important. No matter what system you use to establish it, the stoichiometry has a major impact on the quality of iPS cells." Other studies have noted stoichiometry effects, but Woltjen's team is the first to propose variation in a single factor's mRNA sequence as a determining factor in establishing stoichiometry. Supporting their hypothesis, appending Klf4S with the missing nine amino acids switched the Klf4 expression and reprogramming dynamics to mirror those seen with Klf4L.

Moreover, these differences in stoichiometry were reflected in gene expression patterns observed during the reprogramming process. Although reprogramming with either Klf4S or Klf4L led to the activation of many hallmark reprogramming genes, the majority of gene regulation was clearly dissimilar. Studying the reprogramming process induced by eight different polycistronic vectors, the team observed that both reprogramming performance and gene expression bifurcated with the Klf4 isoform. This finding may suggest that for popular vectors containing Klf4S, a simple modification of the Klf4 length could augment the number of properly reprogrammed cells. For researchers studying the reprogramming process itself, such vector differences raise caution when directly comparing reprogramming data between labs.

Interestingly, the differences associated with Klf4 length appeared mainly when reprogramming with polycistronic vectors. If instead either Klf4S or Klf4L was induced using a monocistronic vector in combination with an OSM polycistronic vector, the isoform dependency of reprogramming disappeared. These results suggest that the polycistronic design of the vector has some innate effect on the expression level of Klf4, while the protein function itself may not be affected. Nevertheless, inappropriate ratios of monocistronic vectors could also lead to a similar stoichiometry effect. Shin-Il Kim, Ph.D., first author of the study, stresses that just recognizing OSKM is not enough when reprogramming and that one must also be aware of the relative expression of the four genes. "Initially, we had no idea how much of a difference it [the 9 amino acids] would make. It goes to show how important it is to really know the materials you are working with."

Explore further: Carcinogenic mechanism of incomplete cell reprogramming in vivo

More information: Shin-Il Kim, Fabian Oceguera-Yanez, Ryoko Hirohata, Sara Linker, Keisuke Okita, Yasuhiro Yamada, Takuya Yamamoto, Shinya Yamanaka, and Knut Woltjen. KLF4 N-Terminal Variance Modulates Induced Reprogramming to Pluripotency. Stem Cell Reports, 2015.

A research team led by the group of Professor Yasuhiro Yamada, Center for iPS Cell Research and Application (CiRA), Kyoto University, has discovered that when cells are subjected to incomplete reprogramming ...

Austin Smith and his research team at the Centre for Stem Cell Research in Cambridge have just published in the journal Development a new and safer way of generating pluripotent stem cells - the stem cells that can give r ...

Go here to see the original:
OSKM stoichiometry determines iPS cell reprogramming

Boosting A Natural Protection Against Alzheimer's Disease

Contact Information

Available for logged-in reporters only

Newswise Researchers at the University of California, San Diego School of Medicine have identified a gene variant that may be used to predict people most likely to respond to an investigational therapy under development for Alzheimers disease (AD). The study, published March 12 in Cell Stem Cell, is based on experiments with cultured neurons derived from adult stem cells.

Our results suggest that certain gene variants allow us to reduce the amount of beta amyloid produced by neurons, said senior author Lawrence Goldstein, PhD, director of UC San Diego Sanford Stem Cell Clinical Center and UC San Diego Stem Cell Program. This is potentially significant for slowing the progression of Alzheimers disease. AD is the most common cause of dementia in the United States, afflicting one in nine people age 65 and older.

The genetic risk factor investigated are variants of the SORL1 gene. The gene codes for a protein that affects the processing and subsequent accumulation of beta amyloid peptides, small bits of sticky protein that build up in the spaces between neurons. These plaques are linked to neuronal death and related dementia.

Previous studies have shown that certain variants of the SORL1 gene confer some protection from AD, while other variants are associated with about a 30 percent higher likelihood of developing the disease. Approximately one-third of the U.S. adult population is believed to carry the non-protective gene variants.

The studys primary finding is that variants in the SORL1 gene may also be associated with how neurons respond to a natural compound in the brain that normally acts to protect nerve cell health. The protective compound, called BDNF, short for brain-derived neurotrophic factor, is currently being investigated as a potential therapy for a number of neurological diseases, including AD, because of its role in promoting neuronal survival.

For the study, UC San Diego researchers took skin cells from 13 people, seven of whom had AD and six of whom were healthy control subjects, and reprogrammed the skin cells into stem cells. These stem cells were coaxed to differentiate into neurons, and the neurons were cultured and then treated with BDNF.

The experiments revealed that neurons that carried disease-protective SORL1 variants responded to the therapy by reducing their baseline rate of beta amyloid peptide production by, on average, 20 percent. In contrast, the neurons carrying the risk variants of the gene, showed no change in baseline beta amyloid production.

BDNF is found in everyones brain, said first author Jessica Young, PhD, a postdoctoral fellow in the Goldstein laboratory. What we found is that if you add more BDNF to neurons that carry a genetic risk factor for the disease, the neurons dont respond. Those with the protective genetic profile do.

Read more from the original source:
Boosting A Natural Protection Against Alzheimer's Disease

Neuralstem Stock Plunges After Latest Study on ALS Drug

GERMANTOWN, Md. (TheStreet) -- Neuralstem (CUR - Get Report) is providing an overly optimistic picture about its surgical stem-cell therapy for amyotrophic lateral sclerosis (ALS), the degenerative and fatal nerve disease.

Instead of disclosing the results from all 15 ALS patients enrolled in Neuralstem's phase II study of NSI-566, the company decided to only release a comparison between the patients who responded and those who didn't respond. Of course, the seven responders in the study showed more stabilization or improvements in muscle function compared with the eight patients deemed non-responders.

The scientific term for this conclusion is, "Duh."

When you work backwards and do some simple math on the muscle performance of all 15 ALS patients in the Neuralstem study, the results aren't very encouraging. Neuralstem chose to stay mum on this more customary analysis.

Neuralstem shares are down 14% to $3.21 in Thursday trading.

Read this article:
Neuralstem Stock Plunges After Latest Study on ALS Drug

Hip and shoulder arthritis six months after bone marrow stem cell therapy by Harry Adelson ND – Video


Hip and shoulder arthritis six months after bone marrow stem cell therapy by Harry Adelson ND
Mareen describes her outcome six months after her bone marrow stem cell treatment by Harry Adelson ND for arthritis of her hip and shoulder http://www.docereclinics.com.

By: Harry Adelson, N.D.

Read more:
Hip and shoulder arthritis six months after bone marrow stem cell therapy by Harry Adelson ND - Video